Under various circumstances, the Food and Drug Administration may require a drug maker to run a post-marketing study, but a large percentage of these studies are still pending, according to the latest agency analysis.

As of the end of fiscal year 2016, 86 percent of required studies were still pending, which meant they were not yet under way. An average of 261 post-marketing requirements were made each year since fiscal year 2010, and most that were established several years ago were since fulfilled or released. Of the required studies pending as of September 30, 2016, 83 percent were created within the past three years, according to the FDA analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy